Table of Contents Author Guidelines Submit a Manuscript
Journal of Thyroid Research
Volume 2015, Article ID 438235, 8 pages
http://dx.doi.org/10.1155/2015/438235
Research Article

Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments

1Bayer Healthcare Pharmaceuticals Inc., Whippany, NJ 07981, USA
2RTI Health Solutions, Research Triangle Park, NC 27709, USA

Received 29 September 2015; Accepted 12 November 2015

Academic Editor: Noriyuki Koibuchi

Copyright © 2015 Ateesha F. Mohamed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCON 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at Google Scholar
  2. N. L. Busaidy and M. E. Cabanillas, “Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease,” Journal of Thyroid Research, vol. 2012, Article ID 618985, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. NCCN, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Thyroid Carcinoma Version 1.2015, 2015, http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
  4. F. Pacini, M. G. Castagna, L. Brilli, and G. Pentheroudakis, “Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 23, supplement 7, pp. vii110–vii119, 2012. View at Publisher · View at Google Scholar
  5. C. F. A. Eustatia-Rutten, E. P. M. Corssmit, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. W. Smit, “Survival and death causes in differentiated thyroid carcinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 313–319, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. J. O'Neill, J. Oucharek, D. Learoyd, and S. B. Sidhu, “Standard and emerging therapies for metastatic differentiated thyroid cancer,” Oncologist, vol. 15, no. 2, pp. 146–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Durante, N. Haddy, E. Baudin et al., “Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 2892–2899, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Schlumberger, M. Brose, R. Elisei et al., “Definition and management of radioactive iodine-refractory differentiated thyroid cancer,” The Lancet Diabetes and Endocrinology, vol. 2, no. 5, pp. 356–358, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Dadu and M. E. Cabanillas, “Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions,” Minerva Endocrinologica, vol. 37, no. 4, pp. 335–356, 2012. View at Google Scholar · View at Scopus
  10. K. Shimaoka, D. A. Schoenfeld, W. D. DeWys, R. H. Creech, and R. DeConti, “A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma,” Cancer, vol. 56, no. 9, pp. 2155–2160, 1985. View at Publisher · View at Google Scholar · View at Scopus
  11. S. D. Williams, R. Birch, and L. H. Einhorn, “Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group trial,” Cancer Treatment Reports, vol. 70, no. 3, pp. 405–407, 1986. View at Google Scholar · View at Scopus
  12. R. W. Tsang, J. D. Brierley, W. J. Simpson, T. Panzarella, M. K. Gospodarowicz, and S. B. Sutcliffe, “The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma,” Cancer, vol. 82, no. 2, pp. 375–388, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. E. Nikiforov, “Molecular diagnostics of thyroid tumors,” Archives of Pathology and Laboratory Medicine, vol. 135, no. 5, pp. 569–577, 2011. View at Google Scholar · View at Scopus
  14. E. Baudin and M. Schlumberger, “New therapeutic approaches for metastatic thyroid carcinoma,” Lancet Oncology, vol. 8, no. 2, pp. 148–156, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Xing, “Recent advances in molecular biology of thyroid cancer and their clinical implications,” Otolaryngologic Clinics of North America, vol. 41, no. 6, pp. 1135–1146, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. S. Brose, C. M. Nutting, B. Jarzab et al., “Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial,” The Lancet, vol. 384, no. 9940, pp. 319–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Schlumberger, M. Tahara, L. J. Wirth et al., “Lenvatinib versus placebo in radioiodine-refractory thyroid cancer,” The New England Journal of Medicine, vol. 372, no. 7, pp. 621–630, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. J. F. P. Bridges, A. B. Hauber, D. Marshall et al., “Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force,” Value in Health, vol. 14, no. 4, pp. 403–413, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. L. L. Thurstone, “A law of comparative judgment,” Psychological Review, vol. 34, no. 4, pp. 273–286, 1927. View at Publisher · View at Google Scholar · View at Scopus
  20. D. McFadden, “Conditional logit analysis of qualitative choice behavior,” in Frontiers in Econometrics, P. Zarembka, Ed., pp. 105–142, Academic Press, New York, NY, USA, 1974. View at Google Scholar
  21. M. D. Clark, D. Determann, S. Petrou, D. Moro, and E. W. de Bekker-Grob, “Discrete choice experiments in health economics: a review of the literature,” PharmacoEconomics, vol. 32, pp. 883–902, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Marshall, J. F. P. Bridges, B. Hauber et al., “Conjoint analysis applications in health—how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008,” Patient, vol. 3, no. 4, pp. 249–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. B. Hauber, J. Arellano, Y. Qian et al., “Patient preferences for treatments to delay bone metastases,” Prostate, vol. 74, no. 15, pp. 1488–1497, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Hechmati, A. B. Hauber, J. Arellano et al., “Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom,” Supportive Care in Cancer, vol. 23, no. 1, pp. 21–28, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. J. F. P. Bridges, A. F. Mohamed, H. W. Finnern, A. Woehl, and A. B. Hauber, “Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis,” Lung Cancer, vol. 77, no. 1, pp. 224–231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. F. Mohamed, A. B. Hauber, and M. P. Neary, “Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma,” PharmacoEconomics, vol. 29, no. 11, pp. 977–988, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. A. B. Hauber, N. K. Arden, A. F. Mohamed et al., “A discrete-choice experiment of United Kingdom patients' willingness to risk adverse events for improved function and pain control in osteoarthritis,” Osteoarthritis and Cartilage, vol. 21, no. 2, pp. 289–297, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. F. R. Johnson, E. Lancsar, D. Marshall et al., “Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force,” Value in Health, vol. 16, no. 1, pp. 3–13, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. W. F. Kuhfeld, Marketing Research Methods in SAS: Experimental Design, Choice, Conjoint, and Graphical Techniques, SAS Institute, Cary, NC, USA, 2010.
  30. K. E. Train, Discrete Choice Methods With Simulation, Cambridge University Press, Cambridge, UK, 2003. View at Publisher · View at Google Scholar · View at MathSciNet
  31. K. Train and G. Sonnier, “Mixed logit with bounded distributions of correlated partworths,” in Applications of Simulation Methods in Environmental and Resource Economics, R. Scarpa and A. Alberini, Eds., pp. 117–134, Springer, Dordrecht, The Netherlands, 2005. View at Google Scholar
  32. D. A. Hensher, J. M. Rose, and W. H. Greene, Applied Choice Analysis, Cambridge University Press, Cambridge, UK, 2005.
  33. M. K. Wong, A. F. Mohamed, A. B. Hauber et al., “Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma,” Journal of Medical Economics, vol. 15, no. 6, pp. 1139–1148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. F. R. Johnson, G. Van Houtven, S. Özdemir et al., “Multiple sclerosis patients' benefit-risk preferences: Serious adverse event risks versus treatment efficacy,” Journal of Neurology, vol. 256, no. 4, pp. 554–562, 2009. View at Publisher · View at Google Scholar · View at Scopus